ライフサイエンスコーパス: dermatomyositis

1 nflammatory myopathy (i.e., polymyositis and dermatomyositis).

2 tissue of adult dermatomyositis and juvenile dermatomyositis.

3 human autoimmune settings including juvenile dermatomyositis.

4 ontributions to the pathogenesis of juvenile dermatomyositis.

5 e type 1 interferon pathway for treatment of dermatomyositis.

6 rse effects in patients with polymyositis or dermatomyositis.

7 ts, 54 with inflammatory myopathies, 14 with dermatomyositis.

8 juvenile idiopathic arthritis, and juvenile dermatomyositis.

9 losporin in children with new-onset juvenile dermatomyositis.

10 inent data from adults with polymyositis and dermatomyositis.

11 c control of the immune response in juvenile dermatomyositis.

12 small vessel occlusion in untreated juvenile dermatomyositis.

13 ear cells from children with active juvenile dermatomyositis.

14 d genetics play in the evolution of juvenile dermatomyositis.

15 derstanding the etiopathogenesis of juvenile dermatomyositis.

16 perimysial blood vessels in 10 patients with dermatomyositis.

17 disability for adults with polymyositis and dermatomyositis.

18 imately 25% of patients with polymyositis or dermatomyositis.

19 enes are very strongly associated with adult dermatomyositis.

20 the 198 developed cancer after diagnosis of dermatomyositis.

21 h juvenile idiopathic arthritis and juvenile dermatomyositis.

22 d in serum of patients with polymyositis and dermatomyositis.

23 is of perifascicular muscle fibre atrophy in dermatomyositis.

24 atory myopathy, and the typical skin rash of dermatomyositis.

25 ammatory myopathies such as polymyositis and dermatomyositis.

26 flammatory demyelinating polyneuropathy, and dermatomyositis.

27 er inclusion body myositis, polymyositis, or dermatomyositis.

28 stemic sclerosis, morphea, hidradenitis, and dermatomyositis.

29 refractory systemic lupus erythematosus and dermatomyositis.

30 e populous in lesional skin of patients with dermatomyositis.

31 romising therapeutic strategy in adults with dermatomyositis.

32 wide association study has been performed in dermatomyositis.

33 a differentiation-associated gene 5-positive dermatomyositis.

34 the diagnostic utility of autoantibodies in dermatomyositis.

35 ties between muscle and skin inflammation in dermatomyositis.

36 s a disease activity marker specifically for dermatomyositis.

37 e all manifestations of skin inflammation in dermatomyositis.

38 ifestations, and therapy for skin disease in dermatomyositis.

39 an important role in systemic sclerosis and dermatomyositis.

40 ad in regions of muscle fiber abnormality in dermatomyositis.

41 ans independently scored 10 children (9 with dermatomyositis, 1 with polymyositis; ages 4-15 years) t

42 d 3 pairs of monozygotic twins with juvenile dermatomyositis, 11 families with other siblings or rela

43 tigen in the human connective tissue disease dermatomyositis [14,15].

44 erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eight had ankylosin

45 erythematosus (3.06 [95% CI 1.78-4.90]) and dermatomyositis (2.64 [95% CI 0.86-6.17]) but not for sy

46 h to allow separate statistical analysis (47 dermatomyositis, 223 controls).

47 81% White, mean age 55.5 +/- 13.4 years,52% Dermatomyositis, 39% Polymyositis, 9% Necrotizing Myopat

48 was characterized by a higher proportion of dermatomyositis (69% of adult Mestizos versus 35% of adu

49 In dermatomyositis, a multiorgan disease, evidence exists t

50 ells contribute to the pathogenesis of adult dermatomyositis, a photoinduced autoimmune skin disease.

51 association of this polymorphism with adult dermatomyositis, a photosensitive disease that exhibits

52 Patients with juvenile dermatomyositis, a systemic autoimmune disease, displaye

53 be organized under two headings--amyopathic dermatomyositis (ADM) and classic dermatomyositis (CDM).

54 Among 8 patients with recalcitrant cutaneous dermatomyositis (all women; mean [SD] age, 54 [15.9] yea

55 who developed classic cutaneous findings of dermatomyositis along with proximal muscle weakness and

56 e frequency of the -308A allele was 0.26 for dermatomyositis and 0.14 for controls (p = 0.014).

57 Fifty adult patients with dermatomyositis and 239 healthy, race-matched controls w

58 ion may influence the relative prevalence of dermatomyositis and anti-Mi-2 autoantibodies in the US.

59 In both dermatomyositis and Duchenne dystrophy, C5-b9 deposits c

60 ment-induced microangiopathy is important in dermatomyositis and in the rare disorder, necrotizing my

61 ears, with particular focus on polymyositis, dermatomyositis and inclusion body myositis.

62 Most data for treatment of dermatomyositis and juvenile dermatomyositis are from an

63 n found abundantly in muscle tissue of adult dermatomyositis and juvenile dermatomyositis.

64 alpha, are present in substantial numbers in dermatomyositis and may account for most of the cells pr

65 ime of onset with the relative prevalence of dermatomyositis and myositis autoantibodies in 380 patie

66 All patients with dermatomyositis and polymyositis (> or =15 years old) we

67 Dermatomyositis and polymyositis are associated with can

68 Dermatomyositis and polymyositis are treatable disorders

69 ratios (SIR) for individual cancer sites for dermatomyositis and polymyositis separately, using natio

70 syndromes of chronic inflammatory myopathy (dermatomyositis and polymyositis) may have in certain in

71 In both dermatomyositis and polymyositis, risk of malignant dise

72 re is increasing evidence of autoimmunity in dermatomyositis and polymyositis, with strong correlatio

73 nd, placebo-controlled therapeutic trials of dermatomyositis and polymyositis.

74 of specific cancer types in individuals with dermatomyositis and polymyositis.

75 tissues in patients with SS from those with dermatomyositis and provide a relative weighting of the

76 In individual patients with dermatomyositis and some with polymyositis, a blood type

77 fundamental mechanistic differences between dermatomyositis and subacute cutaneous lupus erythematos

78 Dermatomyositis and systemic lupus erythematosus (lupus)

79 Children and adolescents with juvenile dermatomyositis and systemic lupus erythematosus also ex

80 tibodies found in the serum of patients with dermatomyositis and systemic lupus erythematosus, is rap

81 nous cyclophosphamide in refractory juvenile dermatomyositis and tacrolimus ointment for the dermatol

82 erstanding of autoantibodies associated with dermatomyositis and the autoimmune necrotizing myopathie

83 r with autoantibodies found in patients with dermatomyositis and the autoimmune necrotizing myopathie

84 genetics of children affected with juvenile dermatomyositis and the impact these genes have on disea

85 Advances in dermatomyositis and the juvenile idiopathic inflammatory

86 rproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythe

87 tities, but is primarily made up of juvenile dermatomyositis and, to a lesser degree, juvenile polymy

88 ith systemic illnesses (lupus erythematosus, dermatomyositis), and the skin changes of potentially fa

89 r siblings or relatives with polymyositis or dermatomyositis, and 2 families with inclusion body myos

90 ents with systemic sclerosis, 1 patient with dermatomyositis, and a healthy volunteer were scanned us

91 ific information from children with juvenile dermatomyositis, and includes pertinent data from adults

92 mes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are system

93 on inflammatory myopathies are polymyositis, dermatomyositis, and inclusion body myositis.

94 roup of diseases that includes polymyositis, dermatomyositis, and inclusion body myositis.

95 i myopathy, nemaline myopathy, polymyositis, dermatomyositis, and inclusion body myositis].

96 Systemic lupus erythematosus, juvenile dermatomyositis, and juvenile localized scleroderma stan

97 argets include scleroderma, cystic fibrosis, dermatomyositis, and lupus, all of which represent unmet

98 cirrhosis, Sjogren syndrome, systemic lupus, dermatomyositis, and neonatal lupus.

99 with inclusion-body myositis, polymyositis, dermatomyositis, and neurogenic muscle atrophy, but it i

100 ce of systemic lupus erythematosus, juvenile dermatomyositis, and other primary systemic vasculitides

101 antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sjogren's syndrome.

102 sitis (anti-SAE autoantibodies) and juvenile dermatomyositis (anti-p155/140 autoantibodies) (anti-MJ

103 ntibodies have been described in adult-onset dermatomyositis (anti-SAE autoantibodies) and juvenile d

104 or treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case

105 ients with HL, sensorimotor neuropathies and dermatomyositis are more frequent in NHL.

106 phil cytoplasmic antibodies+ vasculitis, and dermatomyositis are noteworthy but must be interpreted w

107 histocompatibility complex in early juvenile dermatomyositis are reported.

108 Inclusion body myositis, polymyositis, and dermatomyositis are three distinct categories of inflamm

109 articularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulat

110 be an important part of the pathogenesis of dermatomyositis, as it appears to be in systemic lupus e

111 erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferono

112 verse effects related to ipilimumab therapy, dermatomyositis associated with this agent has not previ

113 sequenced peptides eluted from the juvenile dermatomyositis-associated class II allele HLA-DQalpha1*

114 effective for the cutaneous complications of dermatomyositis but has been helpful in other extramuscu

115 available for evaluating the skin disease of dermatomyositis, but there is a need for new effective t

116 the reversibility of microvascular damage in dermatomyositis by intravenous immune globulin which app

117 amyopathic dermatomyositis (ADM) and classic dermatomyositis (CDM).

118 tion of -308A and HLA-DR3 in Caucasians with dermatomyositis compared to controls.

119 5) dermatopulmonary syndrome is a subset of dermatomyositis defined by specific clinical features an

120 are certainly effective in polymyositis and dermatomyositis despite the lack of randomized controlle

121 l in DM showed that improvement in Cutaneous Dermatomyositis Disease Area and Severity Index Activity

122 T cells correlated positively with Cutaneous Dermatomyositis Disease Area and Severity Index scores (

123 es 1, 2, and 2a, and had to have a Cutaneous Dermatomyositis Disease Area and Severity Index-Activity

124 ing patients with polymyositis (PM) (n=114), dermatomyositis (DM) (n=102), myositis associated with a

125 l muscle metabolism in vivo in patients with dermatomyositis (DM) and polymyositis (PM) in order to e

126 c acidosis and stroke-like episodes (MELAS), dermatomyositis (DM) and polymyositis (PM) using pairwis

127 non-inflammatory or dystrophic controls, two dermatomyositis (DM) and two polymyositis (PM) patients

128 ts have confirmed that polymyositis (PM) and dermatomyositis (DM) are not genetically identical disea

129 have estimated that up to 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to

130 Juvenile dermatomyositis (DM) is a chronic inflammatory myopathy

131 Dermatomyositis (DM) is a rare multisystem autoimmune di

132 Dermatomyositis (DM) is a rare, systemic autoimmune dise

133 Juvenile dermatomyositis (DM) is an autoimmune disease of childho

134 Dermatomyositis (DM) is an autoimmune disease, which is

135 Dermatomyositis (DM) is associated with increased rates

136 Except when the diagnosis of juvenile dermatomyositis (DM) is in doubt, a case has not been ma

137 The accumulated mucin in non-Gottron's dermatomyositis (DM) lesions is primarily chondroitin-4-

138 fication of novel autoantibodies in juvenile dermatomyositis (DM) may have etiologic and clinical imp

139 mporal clustering of a cancer diagnosis with dermatomyositis (DM) onset is strikingly associated with

140 ts with polymyositis (PM) than in those with dermatomyositis (DM) or other myositis syndromes.

141 (PM) and adults and children with refractory dermatomyositis (DM) were enrolled.

142 Sera from 20 adult patients with dermatomyositis (DM) were screened for autoantibodies.

143 before and after therapy from patients with dermatomyositis (DM) who improved and patients with incl

144 vidence points toward an association between dermatomyositis (DM) with malignancy.

145 -like modifier, and its enzymatic pathway in dermatomyositis (DM), an autoimmune disease primarily in

146 f the diverse entities of polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM),

147 ), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), and normal or disease controls.

148 symptom onset and the prevalence of juvenile dermatomyositis (DM), compared to juvenile polymyositis

149 ysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and non-myopathic muscl

150 rs of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treat

151 To properly evaluate therapies for cutaneous dermatomyositis (DM), it is essential to administer an o

152 and 15 muscle samples from 44 patients with dermatomyositis (DM), polymyositis (PM), inclusion body

153 immune inflammatory muscle disorders include Dermatomyositis (DM), Polymyositis (PM), Necrotizing Myo

154 For Caucasian patients with dermatomyositis (DM), the Gm 3 23 5,13 phenotype was a r

155 atients at the time of diagnosis of juvenile dermatomyositis (DM), to compare the RANKL:osteoproteger

156 stituents of muscle inflammation in juvenile dermatomyositis (DM).

157 tained from children diagnosed with juvenile dermatomyositis (DM).

158 f low-producing MBL polymorphisms with adult dermatomyositis (DM).

159 lung disease and either polymyositis (PM) or dermatomyositis (DM).

160 nificance of the cutaneous manifestations of dermatomyositis (DM).

161 eases they were designed to treat, including dermatomyositis (DM).

162 autoantibody is specifically associated with dermatomyositis (DM).

163 found in a distinct subset of patients with dermatomyositis (DM).

164 e" is a candidate biomarker in patients with dermatomyositis (DM).

165 n implicated in the pathogenesis of juvenile dermatomyositis (DM).

166 To our knowledge, drug-induced dermatomyositis from ipilimumab has not previously been

167 y technology may also be used to distinguish dermatomyositis from the other inflammatory myopathies,

168 In dermatomyositis, genes induced by interferon-alpha/beta

169 ls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease, Hashimoto thyroiditis,

170 y of the -308A allele was 0.27 in the entire dermatomyositis group, versus 0.14 in the controls (p =

171 tion of the heterogeneity of skin disease in dermatomyositis has already provided evidence that clini

172 e conceptual model of the pathophysiology of dermatomyositis has been based on work extending back ov

173 Type I interferon activity in juvenile dermatomyositis has been demonstrated by both global gen

174 Dermatomyositis has been linked to cancer, particularly

175 Dermatomyositis has been modeled as an autoimmune diseas

176 Cutaneous disease in dermatomyositis has no standardized treatment approach a

177 lesions of patients with cutaneous lupus and dermatomyositis has provided valuable information about

178 Patients with dermatomyositis have a high rate of malignancy.

179 classification criteria for polymyositis and dermatomyositis have been suggested by a number of inves

180 evidence that patients with polymyositis and dermatomyositis have specific clinico-serological profil

181 dies; myovasculopathies, including childhood dermatomyositis; immune polymyopathies, active myopathie

182 Studies in adults with polymyositis and dermatomyositis implicate interleukin-1alpha, transformi

183 MBL variants were over-represented in adult dermatomyositis in a dose-responsive fashion (p=0.0002).

184 allele was positively associated with adult dermatomyositis in a dose-responsive fashion (p=0.0004),

185 adverse events and consider drug-associated dermatomyositis in the differential diagnosis in patient

186 utoantibodies preferentially associated with dermatomyositis include those recognizing Mi-2, MDA5, TI

187 new insights into the disease mechanisms of dermatomyositis, inclusion body myositis, and polymyosit

188 specific response in muscle in patients with dermatomyositis, inclusion body myositis, and polymyosit

189 ing intravenous immunoglobulin in refractory dermatomyositis, indicated benefit.

190 Although evidence remains strong that dermatomyositis is a disorder with an early involvement

191 Dermatomyositis is a microangiopathy affecting skin and

192 Dermatomyositis is a systemic disorder and whereas the s

193 Dermatomyositis is an inflammatory disorder of muscle af

194 We have previously shown that juvenile dermatomyositis is associated with the HLA-DQA1*0501 all

195 We conclude that: perifascicular atrophy in dermatomyositis is consistently associated with focal mi

196 e weakness in patients with polymyositis and dermatomyositis is due to autoimmune and inflammatory pr

197 rization of the type 1 interferon pathway in dermatomyositis is leading down a path of genomic medici

198 Dermatomyositis is one of the idiopathic inflammatory my

199 The pathogenesis of adult dermatomyositis is reviewed here, with particular attent

200 Our results provide evidence that dermatomyositis is strongly associated with a wide range

201 Juvenile dermatomyositis is the most common of the idiopathic inf

202 nective-tissue diseases, especially juvenile dermatomyositis (JDM) and systemic sclerosis; however, l

203 Juvenile dermatomyositis (JDM) is a multisystem autoimmune diseas

204 Juvenile dermatomyositis (JDM) is an immune-mediated inflammatory

205 radiation exposure 1 month prior to juvenile dermatomyositis (JDM) may trigger the onset of disease.

206 Juvenile dermatomyositis (JDM), the most common pediatric inflamm

207 d have been found in high levels in juvenile dermatomyositis (JDM), which may account the frequency o

208 n how to assess the many aspects of juvenile dermatomyositis (JDM).

209 develop in 20-40% of children with juvenile dermatomyositis (juvenile DM), contributing to disease m

210 ematosis, Wegener's granulomatosis, juvenile dermatomyositis, juvenile scleroderma and autoinflammato

211 a, mixed connective tissue disease, juvenile dermatomyositis, juvenile spondyloarthropathy and system

212 ion has now been recognized in patients with dermatomyositis-like disease.

213 fferent pathways of complement activation in dermatomyositis, lupus nephritis, and necrotic muscle fi

214 iption and classification of skin disease in dermatomyositis may allow the clinician to predict more

215 se, immunotherapies to better treat juvenile dermatomyositis may become available in the future.

216 AK-RNA interference was performed in IBM and dermatomyositis mesoangioblasts.

217 egulated pathological pathway genome-wide in dermatomyositis muscle and blood.

218 In contrast, dermatomyositis muscle shows a dominant type I IFN patte

219 e that ISG15, which is highly upregulated in dermatomyositis muscle, does not appear to play a key ro

220 interferons alpha and beta, are prominent in dermatomyositis muscle.

221 their inducible products are upregulated in dermatomyositis muscle.

222 econd-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton my

223 lt patients with polymyositis (PM; n = 134), dermatomyositis (n = 129), or other CTDs (predominantly

224 jogren's syndrome (n = 30), polymyositis and dermatomyositis (n = 30), and progressive systemic scler

225 yositis and of an IFN-alpha/beta response in dermatomyositis, neither of which was previously describ

226 ith the relative proportion of patients with dermatomyositis (odds ratio [OR] 2.3, 95% confidence int

227 for our understanding of muscle pathology in dermatomyositis of both adults and children.

228 We identified 618 cases of dermatomyositis, of whom 198 had cancer.

229 Ninety-six patients with adult-onset dermatomyositis or polymyositis had a baseline assessmen

230 muscle function in patients with established dermatomyositis or polymyositis receiving chronic medica

231 or rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of

232 itis patients but in only 1/28 patients with dermatomyositis or polymyositis.

233 l haplotype; however, African Americans with dermatomyositis or with anti-Jo-1 autoantibodies shared

234 temic disease such as lupus erythematosus or dermatomyositis, or be an early symptom of a rare group

235 scular complement deposition is a feature of dermatomyositis pathology but the trigger for complement

236 In the dermatomyositis patient, the en face D-OCT images showed

237 from that of p155 antibody-negative juvenile dermatomyositis patients (P = 0.003).

238 antigenic target on the endothelial cell in dermatomyositis patients and the pathogenic role of the

239 In adult dermatomyositis patients homozygous for the wild-type TN

240 In adult dermatomyositis patients with one variant TNFalpha-308 A

241 Juvenile dermatomyositis patients with p155 autoantibody had a bi

242 tor-alpha synthesis is increased in juvenile dermatomyositis patients with the tumor necrosis factor-

243 ications for systemic and malignancy risk in dermatomyositis patients, and that there may be several

244 in the same 10, as well as in 40 additional dermatomyositis patients, we searched for vascular depos

245 myositis than in responsive polymyositis and dermatomyositis patients.

246 nd resistin have been detected in tissues of dermatomyositis patients.

247 In juvenile dermatomyositis, peptides from human skeletal myosin pla

248 with a subset of patients with polymyositis/dermatomyositis (PM/DM) complicated by interstitial lung

249 whether sera from patients with polymyositis/dermatomyositis (PM/DM) with or without interstitial lun

250 -55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selection of SSc,

251 , 121 with scleroderma, 86 with polymyositis/dermatomyositis [PM/DM]) and 248 Italian patients with a

252 sus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or scleroderma wh

253 The inflammatory muscle diseases dermatomyositis, polymyositis and inclusion body myositi

254 ell into the typical IIM subclassifications: dermatomyositis, polymyositis and inclusion body myositi

255 pathies (IIMs) are typically subdivided into dermatomyositis, polymyositis and inclusion body myositi

256 esoangioblasts isolated from samples of IBM, dermatomyositis, polymyositis, and control muscles were

257 the results of recent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myosit

258 muscle cells in the inflammatory myopathies (dermatomyositis, polymyositis, and inclusion body myosit

259 iopathic inflammatory myopathies, comprising dermatomyositis, polymyositis, and inclusion body myosit

260 iated into three major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myosit

261 BM patient sera, whereas their prevalence in dermatomyositis, polymyositis, and other neuromuscular d

262 Classification systems of dermatomyositis, polymyositis, and the other idiopathic

263 arison, 2/15 (14%) age-matched patients with dermatomyositis, polymyositis, or necrotizing myopathy,

264 ritis; lupus; scleroderma; Sjogren Syndrome; dermatomyositis/polymyositis; unspecified/mixed CTD; oth

265 nisone plus methotrexate achieved a juvenile dermatomyositis PRINTO 20 improvement (p=0.0228).

266 proportion of patients achieving a juvenile dermatomyositis PRINTO 20 level of improvement (20% impr

267 ic systemic lupus erythematosus and juvenile dermatomyositis, remain life-threatening.

268 d Musculoskeletal and Skin Diseases Juvenile Dermatomyositis Research Registry and the National Pedia

269 py is essential, since both polymyositis and dermatomyositis respond to immunotherapeutic agents.

270 vascular membrane attack complex deposits in dermatomyositis result from activation of the classical

271 d unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis.

272 the dermatologic manifestations of juvenile dermatomyositis seem promising.

273 ow the possibility that, for the first time, dermatomyositis skin disease can serve as a valid outcom

274 te responses to available therapeutics, with dermatomyositis skin disease often relapsing and being r

275 lases HDAC1/2, histone-binding proteins, the dermatomyositis-specific autoantigen Mi2beta, a polypept

276 Thirty-one of 50 dermatomyositis specimens contained C5b-9 reactive endom

277 , and the LX promoter polymorphism) in adult dermatomyositis, subacute cutaneous lupus erythematosus,

278 liminary gene expression studies in juvenile dermatomyositis, systemic lupus erythematosus, and chron

279 and specific prior autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoimmune hemolyti

280 ot observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthriti

281 an inflammatory myopathies (polymyositis and dermatomyositis), the early, widespread appearance of MH

282 ar to what is observed in human polymyositis/dermatomyositis, the mice developed a strong antinuclear

283 n understanding these mechanisms in juvenile dermatomyositis, the most common form of childhood infla

284 In juvenile dermatomyositis, the quantitative magnetic resonance ima

285 lar atrophy, and what is the relationship of dermatomyositis to systemic lupus erythematosus.

286 ols, OR = infinite; two-sided p = 0.02), but dermatomyositis was absent in cases themselves.

287 Family history of dermatomyositis was associated with NHL (7 cases vs. 0 c

288 ation, the association of these two genes in dermatomyositis was significantly less than we previousl

289 To further understand the pathophysiology of dermatomyositis, we used microarrays, computational meth

290 sms in patients with rheumatoid arthritis or dermatomyositis were analyzed by polymerase chain reacti

291 dults aged 18-80 years with skin-predominant dermatomyositis were enrolled during stages 1, 2, and 2a

292 care; whereas those with muscle-predominant dermatomyositis were enrolled in stage 3 and had to have

293 A total of 37 patients with polymyositis or dermatomyositis were randomized (19 to creatine, 18 to p

294 factor -308A polymorphism is associated with dermatomyositis, which suggests a pathophysiologic contr

295 18 years or younger with new-onset juvenile dermatomyositis who had received no previous treatment a

296 affect as many as 20% to 30% of adults with dermatomyositis, will not be addressed in this review.

297 Coculture of monocytes from patients with dermatomyositis with endothelial cells resulted in incre

298 crosis factor-alpha, more common in juvenile dermatomyositis with the tumor necrosis factor-alpha-308

299 They distinguish dermatomyositis with vascular pathology from other infla

300 juvenile idiopathic arthritis, and juvenile dermatomyositis, with special interest on strategies to